Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 802 across all filing types
Latest filing 2009-12-09 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming completes pre-BLA meeting with US FDA for Rhucin submission
Regulatory Filings Classification · 96% confidence The document is a press release from Pharming Group NV dated December 9, 2009, confirming interactions with the US FDA regarding a proposed marketing application (BLA) for their product Rhucin. It discusses regulatory processes (BLA submission, PHS Act) and future steps, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed interim report (IR). It is an announcement about regulatory progress and company development. Since it is a general announcement that doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Director Dealing (DIRS), and it is not announcing the publication of a larger report (RPA), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory/corporate news updates.
2009-12-09 English
PHARMING TO PRESENT AT BIO-EUROPE 2009
Regulatory Filings Classification · 95% confidence The document is a short press release dated October 26, 2009, announcing that the company, Pharming Group NV, will be presenting at the BIO-Europe 2009 conference. It details the date, time, and location of the presentation and provides a brief overview of the company and its products. This type of announcement, which informs investors about participation in an industry event or conference, is best classified as a general announcement or investor-related communication. Since it is not a formal financial report (like 10-K, IR, ER), a specific management change (MANG), or a director's trade (DIRS), and it is an announcement about an upcoming event rather than the presentation material itself, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate update, or potentially Investor Presentation (IP) if the content was the presentation itself, but here it is just the announcement of attendance. Given the options, RNS serves as the appropriate fallback for general corporate news announcements that don't fit a more specific category like DIV or CAP. The document length (2088 chars) also suggests it is an announcement rather than a full report.
2009-10-27 English
Pharming recombinant human C1 inhibitor: results in pre-clinical ischaemic reperfusion model confirm potential for new indications
Regulatory Filings Classification · 96% confidence The document is a press release dated October 22, 2009, announcing the publication of preclinical study results regarding Pharming's recombinant human C1 inhibitor (rhC1INH) for treating ischemia-reperfusion injuries. It details scientific findings, quotes the COO, mentions collaboration with a research institute, and cites the journal publication (Annals of Neurology 2009). It also provides updates on the MAA submission for Rhucin®. This content structure—announcing new scientific/clinical progress and providing business updates in a news format—is characteristic of an Earnings Release (ER) or a general press release that doesn't fit a specific regulatory filing type like 10-K, IR, or a specific corporate action (like DIV or CAP). Since it is announcing results and progress, and is not a full transcript (CT) or a formal quarterly report (IR), the best fit among the provided options for a general, timely announcement of business/scientific progress is Earnings Release (ER), although it is not explicitly an earnings report. Given the options, ER is often used for significant operational/scientific announcements, or RNS as a general regulatory filing fallback. However, because it details scientific results and business progress, it functions similarly to an ER announcing positive developments. Since it is not a formal regulatory filing like 10-K or IR, and it is a news announcement, ER is the most appropriate classification for a significant operational update presented as a press release.
2009-10-23 English
Pharming announces third quarter 2009 results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first nine months of 2009, containing detailed financial statements (Statement of financial position, Statement of income, Statement of cash flows), key financial data, and a management discussion of results and financial transactions. It is not a mere announcement (RPA) or a short earnings release, as it provides substantive financial analysis and data tables. Therefore, it is classified as an Interim/Quarterly Report. 9M 2009
2009-10-16 English
Interim / Quarterly Report 2009
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first nine months of 2009, containing detailed financial statements (Statement of financial position, Statement of income, Statement of cash flows), key financial data, and a management discussion of results and financial transactions. It is not a mere announcement (RPA) or a short earnings release, as it provides substantive financial analysis and data tables. Therefore, it is classified as an Interim/Quarterly Report. 9M 2009
2009-10-16 English
Pharming confirms successful closing of offer on convertible bonds
Capital/Financing Update Classification · 99% confidence The document is a press release dated October 13, 2009, announcing the successful closing of an offer related to the conversion of bonds into cash and shares. This action directly involves changes to the company's capital structure (reduction of convertible debt, issuance of new shares, reduction of interest payments). Based on the definitions, this clearly falls under 'Capital/Financing Update' (Code: CAP), as it details fundraising/financing activities and capital structure changes.
2009-10-14 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.